Background: Surgical management has not been encouraged in patients with trisomy 18 (T18) and congenital heart diseases due to poor survival. This study aimed to investigate (1) the appropriateness of palliative surgeries followed by intracardiac repair (ICR) (i.e., two-stage ICR) for patients with a large ventricular septal defect (VSD) and T18, and (2) its impact on their long-term outcomes.
Methods: Medical charts of patients with VSD and T18 who underwent two-stage ICR at the Japanese Red Cross Medical Center between January 2005 and December 2019 were retrospectively reviewed. Demographic data, timing, and types of palliative surgeries, information related to ICR, peri- and postoperative clinical information, postoperative survival, and cause of death were collected. The long-term prognosis of patients treated with two-stage ICR was compared with that of patients treated with primary ICR and palliative surgery without ICR.
Results: Overall, 18 (2 male, 16 female) patients underwent two-stage ICR. Pulmonary artery banding was the initial palliative surgery in all patients after a median duration of 19.5 (range 6-194) days of life. The median age and the mean body weight at the time of ICR were 18.2 (7.6-50.7) months and 6.0 ± 1.0 kg, respectively. The mean pulmonary artery pressure and pulmonary vascular resistance index before ICR were 19.1 ± 7.3 mmHg and 3.4 ± 2.0 U m, respectively. Overall, 17/18 (94%) patients were discharged after ICR. Fourteen (78%) patients were alive during data collection. None of the patients died of cardiac insufficiency, and the median duration of survival was 46.3 (14.3-186.4) months since birth. Most patients required cardiac medications rather than pulmonary vasodilators at the last follow-up. During the study period, three patients underwent primary ICR, and 46 underwent palliative surgery without ICR. Of those who underwent primary ICR, two died in the hospital on the first and 48 day following ICR, and the third died 179 days after the ICR. The Log-rank test revealed a significantly longer survival for the patients treated with two-stage ICR compared with those treated with palliative surgery without ICR (P = 0.003).
Conclusion: Two-stage ICR improves the long-term survival of patients with VSDs and T18. This safe surgical strategy can also prevent pulmonary hypertension in such patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00246-021-02546-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ileocolic resection with temporary ileostomy for Crohn's disease: does it affect long-term disease recurrence compared with primary anastomosis?
ANZ J Surg
September 2024
Department of General Surgery, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Background: We aimed to assess whether the risk of disease recurrence in Crohn's disease (CD) patients that undergone ileocolic resection (ICR) with temporary ileostomy and a later stoma reversal is different compared to patients that underwent a one-stage operation.
Methods: A single-center retrospective review of all patients that underwent elective primary ICR for CD between 2010 and 2022 divided into: 2S-ICR group-patients who underwent two-stage ICR. 1S-ICR group-patients who underwent one-stage ICR.
Can Pyrocarbon be used as a functional spacer for the treatment of recalcitrant shoulder infections?
JSES Int
January 2024
ICR-Institut de Chirurgie Réparatrice, Groupe Kantys, Nice, France.
Background: The most common treatment approach in periprosthetic joint infection (PJI) and chronic shoulder joint infection (SJI) is a two-stage revision involving interval placement of an antibiotic cement spacer or a resection arthroplasty. Knowing that Pyrocarbon has a smooth surface that prevents pathogen adhesion, the question arises whether it could be used as a temporary or permanent functional spacer?
Purpose: The primary objective of the present study was to assess the rate of infection eradication after temporary or definitive implantation of Pyrocarbon Interposition Shoulder Arthroplasty (PISA) in patients with recalcitrant PJI or SJI. Our secondary objective was to assess mid-term clinical and radiographic outcomes.
Molecular-level insights into the transformation and degradation pathways of dissolved organic matter during full-scale swine wastewater treatment.
Sci Total Environ
January 2024
School of Environmental Studies, China University of Geosciences, Wuhan 430074, Hubei, China; National Engineering Research Center of Industrial Wastewater Detoxication and Resource Recovery, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, 100085 Beijing, China. Electronic address:
The rapid development of swine farming has resulted in the generation of a large amount of swine wastewater (SW), and dissolved organic matter (DOM) has a crucial role in determining the efficiency and safety of SW treatment. In this study, the transformation and influential mechanisms of DOM on the quality of SW effluent during full-scale SW treatment in actual engineering were systematically investigated using multispectral analysis and the Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) technique. The results showed that S-containing, reduced, saturated, and less aromatic molecules were preferentially removed in the C-AF, while C-S preferentially removed reduced, unsaturated, and aromatic molecules, as well as molecules with large molecular weights.
View Article and Find Full Text PDFClindamycin Efficacy for Shoulder Device-Related Infections.
Antibiotics (Basel)
April 2022
Infectious Diseases Department, Université Côte d'Azur, CHU Nice, 06202 Nice, France.
Unlabelled: Clindamycin is an antibiotic with high bioavailability and appropriate bone diffusion, often proposed as an alternative in guidelines for prosthetic joint infections. We aimed to evaluate the efficacy of clindamycin in the treatment of shoulder implant joint infections (SIJI).
Methods: A retrospective analysis was conducted at the University Hospital of Nice (France) between 2010 and 2019.
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
J Immunother Cancer
January 2022
Experimental Cancer Medicine, The Institute of Cancer Research, London, UK
Background: Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion and thus enhancing anti-PD-1/PD-L1 efficacy.
Methods: This phase I/II study enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) or advanced non-small cell lung cancer (NSCLC). The primary objectives of phase I were to investigate the safety and tolerability of isatuximab (anti-CD38 monoclonal antibody)+cemiplimab (anti-PD-1 monoclonal antibody, Isa+Cemi) in patients with mCRPC (naïve to anti-PD-1/PD-L1 therapy) or NSCLC (progressed on anti-PD-1/PD-L1-containing therapy).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!